All lobbying filings

TODD STRATEGY GROUP

Lobbying for ALEXION PHARMACEUTICALS, INC. · Biopharmaceutical Company.

Filing 2nd Quarter - Termination

2nd Quarter (Apr 1 - June 30) 2025 · Massachusetts · House · Senate · $80,000.00 income · posted Oct 14, 2025

Official filing document

Bills named in this filing 3

S 864
HELP Copays Act
HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act

Lobbying activity 2

Medicare/Medicaid

340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

Health Issues

General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.